Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Sells 1,500 Shares of Stock

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 1,500 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $142.18, for a total transaction of $213,270.00. Following the sale, the executive vice president now owns 26,571 shares in the company, valued at $3,777,864.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, January 13th, Michael Patrick Miller sold 1,500 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $146.78, for a total transaction of $220,170.00.
  • On Monday, December 9th, Michael Patrick Miller sold 1,500 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $149.12, for a total transaction of $223,680.00.

JAZZ stock opened at $140.85 on Friday. The company’s 50 day moving average price is $146.52 and its 200 day moving average price is $137.40. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals PLC has a fifty-two week low of $116.52 and a fifty-two week high of $154.24. The firm has a market capitalization of $8.03 billion, a price-to-earnings ratio of 10.26, a PEG ratio of 0.76 and a beta of 1.18.

Several hedge funds have recently added to or reduced their stakes in JAZZ. Bank of Montreal Can increased its stake in shares of Jazz Pharmaceuticals by 368.8% during the fourth quarter. Bank of Montreal Can now owns 888,530 shares of the specialty pharmaceutical company’s stock worth $132,640,000 after buying an additional 699,002 shares during the period. AQR Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals by 47.5% during the fourth quarter. AQR Capital Management LLC now owns 1,966,252 shares of the specialty pharmaceutical company’s stock worth $292,598,000 after buying an additional 633,022 shares during the period. Renaissance Technologies LLC increased its stake in shares of Jazz Pharmaceuticals by 13.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,549,371 shares of the specialty pharmaceutical company’s stock worth $529,850,000 after buying an additional 431,670 shares during the period. Pictet Asset Management Ltd. purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $44,869,000. Finally, Marshall Wace LLP increased its stake in shares of Jazz Pharmaceuticals by 26,395.7% during the fourth quarter. Marshall Wace LLP now owns 252,504 shares of the specialty pharmaceutical company’s stock worth $37,694,000 after buying an additional 251,551 shares during the period. Hedge funds and other institutional investors own 89.15% of the company’s stock.

A number of analysts have issued reports on JAZZ shares. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, November 29th. Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 8th. They set a “neutral” rating and a $153.00 price target on the stock. ValuEngine lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 15th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Co boosted their price target on shares of Jazz Pharmaceuticals from $186.00 to $189.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Jazz Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $166.14.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.